Kanvas receives greenlight for First Patient In (FPI) for Phase 1 clinical trial of KAN-004

Kanvas Biosciences has received the green light to begin enrolling and treating patients in a Phase 1 clinical trial of KAN-004, a live biotherapeutic designed to treat immune checkpoint inhibitor–induced colitis, one of the most common and debilitating toxicities in cancer immunotherapy. The Centre de recherche du CHUM (CRCHUM)-sponsored study, led by Dr. Arielle Elkrief and Dr. Bertrand Routy, will evaluate the safety and tolerability of KAN-004’s >100-strain microbial consortium in patients with immune-related colitis, building on promising FMT-LUMINate data.

See Kanvas’ LinkedIn post for more details.